Compare DCO & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCO | VRDN |
|---|---|---|
| Founded | 1849 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.1B |
| IPO Year | 1995 | 2014 |
| Metric | DCO | VRDN |
|---|---|---|
| Price | $160.70 | $21.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $153.60 | $35.46 |
| AVG Volume (30 Days) | 160.6K | ★ 1.2M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.95 | N/A |
| Revenue | ★ $824,730,000.00 | $5,706,000.00 |
| Revenue This Year | $7.40 | $13.73 |
| Revenue Next Year | $8.59 | $279.00 |
| P/E Ratio | $88.58 | ★ N/A |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $84.76 | $13.18 |
| 52 Week High | $210.39 | $34.29 |
| Indicator | DCO | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 37.43 | 47.84 |
| Support Level | $161.52 | $21.62 |
| Resistance Level | $168.74 | $24.86 |
| Average True Range (ATR) | 5.91 | 0.85 |
| MACD | -1.46 | -0.34 |
| Stochastic Oscillator | 12.28 | 28.08 |
Ducommun Inc provides engineering & manufacturing services for high-performance products & high-cost-of failure applications used in the aerospace and defense, industrial, medical & other industries. The company's reportable segments are Structural Systems & Electronic Systems. Structural Systems designs, engineers, and manufactures various sizes of complex contoured aerostructure components and assemblies, and supplies composite and metal-bonded structures and assemblies. Electronic Systems designs, engineers and manufactures high-reliability electronic and electromechanical products used in technology-driven markets, including A&D and Industrial end-use markets. It generates a maximum of its revenue from the Electronic Systems.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.